The Role of HMGB1 in Cardiovascular Biology: Danger Signals

Antioxidants and Redox Signaling

Volumn 23, Issue 17, 2015, Pages 1351-1369

  Cai, Jingjing ^a,b   Wen, Juan ^a   Bauer, Eileen ^b   Zhong, Hua ^a,b   Yuan, Hong ^a   Chen, Alex F ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; ADAPTIVE IMMUNITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBRAL ARTERY DISEASE; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; OXIDATION REDUCTION STATE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; CARDIOVASCULAR SYSTEM; CORONARY ARTERY DISEASE; IMMUNOLOGY; METABOLISM;

ADAPTIVE IMMUNITY; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CORONARY ARTERY DISEASE; HMGB1 PROTEIN; HUMANS; HYPERTENSION, PULMONARY; IMMUNITY, INNATE; PERIPHERAL ARTERIAL DISEASE;

EID: 84951986578     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6408     Document Type: Review

References (209)

1. Abarbanell AM, Hartley JA, Herrmann JL, Weil BR, Wang Y, Manukyan MC, Poynter JA, Meldrum DR. Exogenous high-mobility group box 1 improves myocardial recovery after acute global ischemia/reperfusion injury. Surgery 149: 329-335, 2011.
2. Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M. HMGB1 in systemic lupus Erythematosus: its role in cutaneous lesions development. Autoimmun Rev 9: 661-665, 2010.
3. Abe S, Hayashi H, Seo Y, Matsuda K, Kamio K, Saito Y, Usuki J, Azuma A, Kudo S, Gemma A. Reduction in serum high mobility group box-1 level by polymyxin Bimmobilized fiber column in patients with idiopathic pulmonary fibrosis with acute exacerbation. Blood Purif 32: 310-316, 2011.
4. Agresti A and Bianchi ME. HMGB proteins and gene expression. Curr Opin Genet Dev 13: 170-178, 2003.
5. Andersson U and Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29: 139-162, 2011.
6. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, Buss S, Autschbach F, Pleger ST, Lukic IK, Bea F, Hardt SE, Humpert PM, Bianchi ME, Mairbaurl H, Nawroth PP, Remppis A, Katus HA, Bierhaus A. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117: 3216-3226, 2008.
7. Andrassy M, Volz HC, Riedle N, Gitsioudis G, Seidel C, Laohachewin D, Zankl AR, Kaya Z, Bierhaus A, Giannitsis E, Katus HA, Korosoglou G. HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction. J Intern Med 270: 245-253, 2011.
8. Andrassy M, Volz HC, Schuessler A, Gitsioudis G, Hofmann N, Laohachewin D, Wienbrandt AR, Kaya Z, Bierhaus A, Giannitsis E, Katus HA, Korosoglou G. HMGB1 is associated with atherosclerotic plaque composition and burden in patients with stable coronary artery disease. PLoS One 7: e52081, 2012.
9. Arroyo-Espliguero R, Avanzas P, Quiles J, Kaski JC. Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis 204: 239-243, 2009.
10. Banerjee S, Friggeri A, Liu G, Abraham E. The Cterminal acidic tail is responsible for the inhibitory effects of HMGB1 on efferocytosis. J Leukoc Biol 88: 973-979, 2010.
11. Bauer EM, Shapiro R, Billiar TR, Bauer PM. High mobility group Box 1 inhibits human pulmonary artery endothelial cell migration via a Toll-like receptor 4-and interferon response factor 3-dependent mechanism(s). J Biol Chem 288: 1365-1373, 2013.
12. Bauer EM, Shapiro R, Zheng H, Ahmad F, Ishizawar D, Comhair SA, Erzurum SC, Billiar TR, Bauer PM. High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol Med 18: 1509-1518, 2012.
13. Bell CW, Jiang W, Reich CF, 3rd, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 291: C1318-C1325, 2006.
14. Bianchi ME and Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 15: 496-506, 2005.
15. Biscetti F, Straface G, De Cristofaro R, Lancellotti S, Rizzo P, Arena V, Stigliano E, Pecorini G, Egashira K, De Angelis G, Ghirlanda G, Flex A. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes 59: 1496-1505, 2010.
16. Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 19: 41-52, 2008.
17. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22: 5551-5560, 2003.
18. Brinkmann V and Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin J Cell Biol 198: 773-783, 2012.
19. Bustin M. Chromatin unfolding and activation by HMGN(∗) chromosomal proteins. Trends Biochem Sci 26: 431-437, 2001.
20. Carta S, Castellani P, Delfino L, Tassi S, Vene R, Rubartelli A. DAMPs and inflammatory processes: the role of redox in the different outcomes. J Leukoc Biol 86: 549-555, 2009.
21. Celona B, Weiner A, Di Felice F, Mancuso FM, Cesarini E, Rossi RL, Gregory L, Baban D, Rossetti G, Grianti P, Pagani M, Bonaldi T, Ragoussis J, Friedman N, Camilloni G, Bianchi ME, Agresti A. Substantial histone reduction modulates genomewide nucleosomal occupancy and global transcriptional output. PLoS Biol 9: e1001086, 2011.
22. Chavakis E, Hain A, Vinci M, Carmona G, Bianchi M. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 100: 204-212, 2007.
23. Chen C, Lin X, Wang J, Tang G, Mu Z, Chen X, Xu J, Wang Y, Zhang Z, Yang GY. Effect of HMGB1 on the paracrine action of EPC promotes post-ischemic neovascularization in mice. Stem Cells 32: 2679-2689, 2014.
24. Christman BW, McPherson CD, Newman JH, King GA, BernardGR, GrovesBM,and Loyd JE.An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327: 70-75, 1992.
25. Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O. Evidence of Toll-like receptor molecules on human platelets. Immunol Cell Biol 83: 196-198, 2005.
26. Czura CJ and Tracey KJ. Targeting high mobility group box 1 as a late-acting mediator of inflammation. Crit Care Med 31: S46-S50, 2003.
27. de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG. HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev 11: 909-917, 2012.
28. Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, Arrigoni G, Bianchi ME. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 152: 1197-1206, 2001.
29. Diao H, Kang Z, Han F, Jiang W. Astilbin protects diabetic rat heart against ischemia-reperfusion injury via blockade of HMGB1-dependent NF-kappaB signaling pathway. Food Chem Toxicol 63: 104-110, 2014.
30. Ditsworth D, Zong WX, Thompson CB. Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem 282: 17845-17854, 2007.
31. Du X, Hu X, Wei J. Postconditioning with rosuvastatin reduces myocardial ischemia-reperfusion injury by inhibiting high mobility group box 1 protein expression. Exp Ther Med 7: 117-120, 2014.
32. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P. HMGB1: guiding immunity from within. Trends Immunol 26: 381-387, 2005.
33. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, Arnold B, Bianchi ME, Manfredi AA, Rovere-Querini P. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174: 7506-7515, 2005.
34. Ertl G and Frantz S. Healing after myocardial infarction. Cardiovasc Res 66: 22-32, 2005.
35. Evankovich J, Cho SW, Zhang R, Cardinal J, Dhupar R, Zhang L, Klune JR, Zlotnicki J, Billiar T, Tsung A. High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem 285: 39888-39897, 2010.
36. Faraco G, Fossati S, Bianchi ME, Patrone M, Pedrazzi M, Sparatore B, Moroni F, Chiarugi A. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem 103: 590-603, 2007.
37. Farmer DG, Ewart MA, Mair KM, Kennedy S. Soluble receptor for advanced glycation end products (sRAGE) attenuates haemodynamic changes to chronic hypoxia in the mouse. Pulm Pharmacol Ther 29: 7-14, 2014.
38. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101: 2652-2660, 2003.
39. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31-47, 2002.
40. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA 92: 7450-7454, 1995.
41. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30: 394-403, 2009.
42. Gargiulo NJ, 3rd. Dobutamine-mediated heme oxygenase-1 induction via P13K and p38 MAPK inhibits high mobility group box 1 protein release and attenuates rat myocardial ischemia/reperfusion injury in vivo. J Surg Res 186: 81-82, 2014.
43. Gerlitz G, Hock R, Ueda T, Bustin M. The dynamics of HMG protein-chromatin interactions in living cells. Biochem Cell Biol 87: 127-137, 2009.
44. Giallauria F, Cirillo P, D'Agostino M, Petrillo G, Vitelli A, PacileoM, Angri V, Chiariello M,Vigorito C. Effects of exercise training on high-mobility group box-1 levels after acute myocardial infarction. J CardFail 17: 108-114, 2011.
45. Giallauria F, Cirillo P, Lucci R, Pacileo M, D'Agostino M, Maietta P, Vitelli A, Chiariello M, Vigorito C. Autonomic dysfunction is associated with high mobility group box-1 levels in patients after acute myocardial infarction. Atherosclerosis 208: 280-284, 2010.
46. Goldstein RS, Gallowitsch-Puerta M, Yang L, Rosas-Ballina M, Huston JM, Czura CJ, Lee DC, Ward MF, Bruchfeld AN, Wang H, Lesser ML, Church AL, Litroff AH, Sama AE, Tracey KJ. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25: 571-574, 2006.
47. Gong W, Li Y, Chao F, Huang G, He F. Amino acid residues 201-205 in C-terminal acidic tail region plays a crucial role in antibacterial activity of HMGB1. J Biomed Sci 16: 83, 2009.
48. Gong W, Zheng Y, Chao F, Li Y, Xu Z, Huang G, Gao X, Li S, He F. The anti-inflammatory activity of HMGB1 A box is enhanced when fused with C-terminal acidic tail. J Biomed Biotechnol 2010: 915234, 2010.
49. Green J and Paget MS. Bacterial redox sensors. Nat Rev Microbiol 2: 954-966, 2004.
50. Hallett JW, Jr. 2014. Peripheral Arterial Disease. Merck Manual Professional Version. www.merckmanuals.com/professional/cardiovascular-disorders/peripheral-arterialdisorders/peripheral-arterial-diseaseqt=&sc=&alt Accessed August 17, 2015.
51. Haraba R, Suica VI, Uyy E, Ivan L, Antohe F. Hyperlipidemia stimulates the extracellular release of the nuclear high mobility group box 1 protein. Cell Tissue Res 346: 361-368, 2011.
52. Haraba R, Uyy E, Suica VI, Ivan L, Antohe F. Fluvastatin reduces the high mobility group box 1 protein expression in hyperlipidemia. Int J Cardiol 150: 105-107, 2011.
53. Hardman CH, Broadhurst RW, Raine AR, Grasser KD, Thomas JO, Laue ED. Structure of the A-domain of HMG1 and its interaction with DNA as studied by heteronuclear three-and four-dimensional NMR spectroscopy. Biochemistry 34: 16596-16607, 1995.
54. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 8: 195-202, 2012.
55. Hashimoto T, Ishii J, Kitagawa F, Yamada S, Hattori K, Okumura M, Naruse H, Motoyama S, Matsui S, Tanaka I, Izawa H,Maruyama I, NomuraM, Ozaki Y. Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 221: 490-495, 2012.
56. Hayakawa K, Mishima K, Irie K, HazekawaM, Mishima S, Fujioka M, Orito K, Egashira N, Katsurabayashi S, Takasaki K, Iwasaki K, Fujiwara M. Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology 55: 1280-1286, 2008.
57. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Mishima S, Fujioka M, Orito K, Egashira N, Iwasaki K, Fujiwara M. Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke 39: 951-958, 2008.
58. Hayakawa K, Miyamoto N, Seo JH, Pham LD, Kim KW, Lo EH, Arai K. High-mobility group box 1 from reactive astrocytes enhances the accumulation of endothelial progenitor cells in damaged white matter. J Neurochem 125: 273-280, 2012.
59. Hayakawa K, Nakano T, Irie K, Higuchi S, Fujioka M, Orito K, Iwasaki K, Jin G, Lo EH, Mishima K, Fujiwara M. Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 30: 871-882, 2010.
60. Hayakawa K, Pham LD, Arai K, Lo EH. High-mobility group box 1: an amplifier of stem and progenitor cell activity after stroke. Acta Neurochir Suppl 118: 31-38, 2013.
61. Hayakawa K, Pham LD, Katusic ZS, Arai K, Lo EH. Astrocytic high-mobility group box 1 promotes endothelial progenitor cell-mediated neurovascular remodeling during stroke recovery. Proc Natl Acad Sci USA 109: 7505-7510, 2012.
62. Hayakawa K, Qiu J, Lo EH. Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke. Ann N Y Acad Sci 1207: 50-57, 2010.
63. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, Jr., White CJ, White J, White RA, Antman EM, Smith SC, Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular S, Society for Vascular S, Society for Cardiovascular A, Interventions, Society for Vascular M, Biology, Society of Interventional R, Guidelines AATFoP, American Association of C, Pulmonary R, National Heart L, Blood I, Society for Vascular N, TransAtlantic Inter-Society C, Vascular Disease F. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 47: 1239-1312, 2006.
64. Hu X, Cui B, Zhou X, Xu C, Lu Z, Jiang H. Ethyl pyruvate reduces myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Mol Biol Rep 39: 227-231, 2012.
65. Hu X, Jiang H, Bai Q, Zhou X, Xu C, Lu Z, Cui B, Wen H. Increased serum HMGB1 is related to the severity of coronary artery stenosis. Clin Chim Acta 406: 139-142, 2009.
66. Hu X, Jiang H, Cui B, Xu C, Lu Z, He B. Preconditioning with high mobility group box 1 protein protects against myocardial ischemia-reperfusion injury. Int J Cardiol 145: 111-112, 2010.
67. Huang JM, Hu J, Chen N, Hu ML. Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke. J Crit Care 28: 792-797, 2013.
68. Hwa JS, Jin YC, Lee YS, Ko YS, Kim YM, Shi LY, Kim HJ, Lee JH, Ngoc TM, Bae KH, Kim YS, Chang KC. 2-methoxycinnamaldehyde from Cinnamomum cassia reduces rat myocardial ischemia and reperfusion injury in vivo due to HO-1 induction. J Ethnopharmacol 139: 605-615, 2012.
69. Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M, Maruyama I. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 16: 136-143, 2007.
70. Ito I, Fukazawa J, Yoshida M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem 282: 16336-16344, 2007.
71. Ito T, Kawahara K, Nakamura T, Yamada S, Nakamura T, Abeyama K, Hashiguchi T, Maruyama I. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost 5: 109-116, 2007.
72. Jiang B and Liao R. The paradoxical role of inflammation in cardiac repair and regeneration. J Cardiovasc Transl Res 3: 410-416, 2010.
73. Jiang W, Fu F, Tian J, Zhu H, Hou J. Curculigoside A attenuates experimental cerebral ischemia injury in vitro and vivo. Neuroscience 192: 572-579, 2011.
74. Jiang WL, Fu FH, Xu BM, Tian JW, Zhu HB, Jian H. Cardioprotection with forsythoside B in rat myocardial ischemia-reperfusion injury: relation to inflammation response. Phytomedicine 17: 635-639, 2010.
75. Jin D, Wu Y, Zhao L, Guo J, Zhang K, Chen Z. Atorvastatin reduces serum HMGB1 levels in patients with hyperlipidemia. Exp Ther Med 4: 1124-1126, 2012.
76. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 130: 545-552, 2006.
77. Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G, Ilyinskaya O, Tararak E, Bobik A. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 24: 2320-2325, 2004.
78. Kanai Y, Hori S, Tanaka T, Yasuoka M, Watanabe K, Aikawa N, Hosoda Y. Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats. Cardiovasc Res 27: 1619-1623, 1993.
79. Kanellakis P, Agrotis A, Kyaw TS, Koulis C, Ahrens I, Mori S, Takahashi HK, Liu K, Peter K, Nishibori M, Bobik A. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 31: 313-319, 2011.
80. Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, Huang J, Yu Y, Fan XG, Yan Z, Sun X, Wang H, Wang Q, Tsung A, Billiar TR, Zeh HJ, 3rd, Lotze MT, Tang D. HMGB1 in health and disease. Mol Aspects Med 40: 1-116, 2014.
81. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of highmobility group box-1 protein. Immunity 29: 21-32, 2008.
82. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, Grone HJ, Brinkmann V, Jenne DE. Netting neutrophils in autoimmune smallvessel vasculitis. Nat Med 15: 623-625, 2009.
83. Kikuchi K, Kawahara K, Tancharoen S, Matsuda F, Morimoto Y, Ito T, Biswas KK, Takenouchi K, Miura N, Oyama Y, Nawa Y, Arimura N, Iwata M, Tajima Y, Kuramoto T, Nakayama K, Shigemori M, Yoshida Y, Hashiguchi T, Maruyama I. The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. J Pharmacol Exp Ther 329: 865-874, 2009.
84. Kikuchi K, Tancharoen S, Ito T, Morimoto-Yamashita Y, Miura N, Kawahara K, Maruyama I, Murai Y, Tanaka E. Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. Int J Mol Sci 14: 18899-18924, 2013.
85. Kim ID and Lee JK. HMGB1-Binding Heptamer Confers Anti-Inflammatory Effects in Primary Microglia Culture. Exp Neurobiol 22: 301-307, 2013.
86. Kim JB, Lim CM, Yu YM, Lee JK. Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J Neurosci Res 86: 1125-1131, 2008.
87. Kim JB, Sig Choi J, Yu YM, Nam K, Piao CS, Kim SW, Lee MH, Han PL, Park JS, Lee JK. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 26: 6413-6421, 2006.
88. Kim S, Kim SY, Pribis JP, Lotze M, Mollen KP, Shapiro R, Loughran P, Scott MJ, Billiar TR. Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol Med 19: 88-98, 2013.
89. Kim SW, Jin Y, Shin JH, Kim ID, Lee HK, Park S, Han PL, Lee JK. Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiol Dis 46: 147-156, 2012.
90. Kitahara T, Takeishi Y, Harada M, Niizeki T, Suzuki S, Sasaki T, Ishino M, Bilim O, Nakajima O, Kubota I. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc Res 80: 40-46, 2008.
91. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med 14: 476-484, 2008.
92. Koga Y, Fujita M, Tsuruta R, Koda Y, Nakahara T, Yagi T, Aoki T, Kobayashi C, Izumi T, Kasaoka S, Yuasa M, Maekawa T. Urinary trypsin inhibitor suppresses excessive superoxide anion radical generation in blood, oxidative stress, early inflammation, endothelial injury in forebrain ischemia/reperfusion rats. Neurol Res 32: 925-932, 2010.
93. Kohlstaedt LA, King DS, Cole RD. Native state of high mobility group chromosomal proteins 1 and 2 is rapidly lost by oxidation of sulfhydryl groups during storage. Biochemistry 25: 4562-4565, 1986.
94. Kohno T, Anzai T, Kaneko H, Sugano Y, Shimizu H, Shimoda M, Miyasho T, Okamoto M, Yokota H, Yamada S, Yoshikawa T, Okada Y, Yozu R, Ogawa S, Fukuda K. High-mobility group box 1 protein blockade suppresses development of abdominal aortic aneurysm. J Cardiol 59: 299-306, 2012.
95. Kohno T, Anzai T, Naito K, Miyasho T, Okamoto M, Yokota H, Yamada S, Maekawa Y, Takahashi T, Yoshikawa T, Ishizaka A, Ogawa S. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res 81: 565-573, 2009.
96. Kutsuna S, Tsuruta R, Fujita M, Todani M, Yagi T, Ogino Y, Igarashi M, Takahashi K, Izumi T, Kasaoka S, Yuasa M, Maekawa T. Cholinergic agonist physostigmine suppresses excessive superoxide anion radical generation in blood, oxidative stress, early inflammation, endothelial injury in rats with forebrain ischemia/reperfusion. Brain Res 1313: 242-249, 2010.
97. Lee W, Ku SK, Bae JW, Bae JS. Inhibitory effects of lycopene on HMGB1-mediated pro-inflammatory responses in both cellular and animal models. Food Chem Toxicol 50: 1826-1833, 2012.
98. Lei C, Lin S, Zhang C, Tao W, Dong W, Hao Z, Liu M, Wu B. Effects of high-mobility group box1 on cerebral angiogenesis and neurogenesis after intracerebral hemorrhage. Neuroscience 229: 12-19, 2013.
99. Lei C, Lin S, Zhang C, Tao W, Dong W, Hao Z, Liu M, Wu B. High-mobility group box1 protein promotes neuroinflammation after intracerebral hemorrhage in rats. Neuroscience 228: 190-199, 2013.
100. Li C, Gao Y, Xing Y, Zhu H, Shen J, Tian J. Fucoidan, a sulfated polysaccharide from brown algae, against myocardial ischemia-reperfusion injury in rats via regulating the inflammation response. Food Chem Toxicol 49: 2090-2095, 2011.
101. Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, Qiang X, Harris HE, Czura CJ, Wang H, Ulloa L, Wang H, Warren HS, Moldawer LL, Fink MP, Andersson U, Tracey KJ, Yang H. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 9: 37-45, 2003.
102. Li Y, Xiang M, Yuan Y, Xiao G, Zhang J, Jiang Y, Vodovotz Y, Billiar TR, Wilson MA, Fan J. Hemorrhagic shock augments lung endothelial cell activation: role of temporal alterations of TLR4 and TLR2. Am J Physiol Regul Integr Comp Physiol 297: R1670-R1680, 2009.
103. Libby P and Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res 116: 307-311, 2015.
104. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
105. Limana F, Germani A, Zacheo A, Kajstura J, Di Carlo ABG, Leoni O, Palumbo R, Battistini L, Rastaldo R, Müller S, Pompilio G, Anversa P, Bianchi M, Capogrossi M. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res 97: e73-e83, 2005.
106. Liu K, Mori S, Takahashi HK, Tomono Y, Wake H, Kanke T, Sato Y, Hiraga N, Adachi N, Yoshino T, Nishibori M. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 21: 3904-3916, 2007.
107. Liu M, Yu Y, Jiang H, Zhang L, Zhang PP, Yu P, Jia JG, Chen RZ, Zou YZ, Ge JB. Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis. Acta Pharmacol Sin 34: 830-836, 2013.
108. Long L, Yang X, Southwood M, Lu J, Marciniak SJ, Dunmore BJ, Morrell NW. Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. Circ Res 112: 1159-1170, 2013.
109. Lotze MT and Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331-342, 2005.
110. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundback P, Valdes-Ferrer SI, Olofsson PS, Kalb T, Roth J, Zou Y, Erlandsson-Harris H, Yang H, Ting JP, Wang H, Andersson U, Antoine DJ, Chavan SS, Hotamisligil GS, Tracey KJ. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488: 670-674, 2012.
111. Macchia A, Marchioli R, Marfisi R, Scarano M, Levantesi G, Tavazzi L, Tognoni G. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 153: 1037-1047, 2007.
112. Maekawa Y, Anzai T, Yoshikawa T, Asakura Y, Takahashi T, Ishikawa S, Mitamura H, Ogawa S. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol 39: 241-246, 2002.
113. Masri FA, Xu W, Comhair SA, Asosingh K, Koo M, Vasanji A, Drazba J, Anand-Apte B, Erzurum SC. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 293: L548-L554, 2007.
114. Maugeri N, Franchini S, Campana L, Baldini M, Ramirez GA, Sabbadini MG, Rovere-Querini P, Manfredi AA. Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity 45: 584-587, 2012.
115. Mazarati A, Maroso M, Iori V, Vezzani A, Carli M. High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and receptor for advanced glycation end products. Exp Neurol 232: 143-148, 2011.
116. McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, hypertensive end-organ damage. Circ Res 116: 1022-1033, 2015.
117. Mehra VC, Ramgolam VS, Bender JR. Cytokines and cardiovascular disease. J Leukoc Biol 78: 805-818, 2005.
118. Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, Lauzon-Joset JF, Breuils-Bonnet S, Tremblay E, Biardel S, Racine C, Courture C, Bonnet P, Majka SM, Deshaies Y, Picard F, Provencher S, Bonnet S. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. J Am Heart Assoc 2: e005157, 2013.
119. Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, Tracey KJ, Chiorazzi N. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 173: 307-313, 2004.
120. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 118: 1486-1495, 2008.
121. Mitola S, Belleri M, Urbinati C, Coltrini D, Sparatore B, Pedrazzi M, Melloni E, Presta M. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 176: 12-15, 2006.
122. Mitroulis I, Kambas K, Chrysanthopoulou A, Skendros P, Apostolidou E, Kourtzelis I, Drosos GI, Boumpas DT, Ritis K. Neutrophil extracellular trap formation is associated with IL-1beta and autophagy-related signaling in gout. PLoS One 6: e29318, 2011.
123. Mori S, Liu K, Takahashi HK, Nishibori M. [Therapeutic effect of anti-nucleokine monoclonal antibody on ischemic brain infarction]. Yakugaku Zasshi 129: 25-31, 2009.
124. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 54: S20-S31, 2009.
125. Murakami K, Koide M, Dumont TM, Russell SR, Tranmer BI, Wellman GC. Subarachnoid hemorrhage induces gliosis and increased expression of the pro-inflammatory cytokine high mobility group box 1 protein. Transl Stroke Res 2: 72-79, 2011.
126. Nakahara T, Tsuruta R, Kaneko T, Yamashita S, Fujita M, Kasaoka S, Hashiguchi T, Suzuki M, Maruyama I, Maekawa T. High-mobility group box 1 protein in CSF of patients with subarachnoid hemorrhage. Neurocrit Care 11: 362-368, 2009.
127. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94: 1543-1553, 2004.
128. Nogueira-Machado JA, Volpe CM, Veloso CA, Chaves MM. HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert Opin Ther Targets 15: 1023-1035, 2011.
129. Nystrom S, Antoine DJ, Lundback P, Lock JG, Nita AF, Hogstrand K, Grandien A, Erlandsson-Harris H, Andersson U, Applequist SE. TLR activation regulates damage-associated molecular pattern isoforms released during pyroptosis. EMBO J 32: 86-99, 2013.
130. Oozawa S, Mori S, Kanke T, Takahashi H, Liu K, Tomono Y, Asanuma M, Miyazaki I, Nishibori M, Sano S. Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circ J 72: 1178-1184, 2008.
131. Oozawa S, Sano S, Nishibori M. Usefulness of high mobility group box 1 protein as a plasma biomarker in patient with peripheral artery disease. Acta Med Okayama 68: 157-162, 2014.
132. Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, Ballantyne CM, Gahmberg CG, Bianchi ME, Nawroth PP, Chavakis T. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 26: 1129-1139, 2007.
133. Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, Marcu KB, Bianchi ME. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 179: 33-40, 2007.
134. Panigrahi S, Ma Y, Hong L, Gao D, West XZ, Salomon RG, Byzova TV, Podrez EA. Engagement of platelet toll-like receptor 9 by novel endogenous ligands promotes platelet hyperreactivity and thrombosis. Circ Res 112: 103-112, 2013.
135. Paoletti R, Gotto AJ, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation 109: III20-III26, 2004.
136. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370-7377, 2004.
137. Park S and Lippard SJ. Redox state-dependent interaction of HMGB1 and cisplatin-modified DNA. Biochemistry 50: 2567-2574, 2011.
138. Porto A, Palumbo R, Pieroni M, Aprigliano G, Chiesa R, Sanvito F, Maseri A, Bianchi ME. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J 20: 2565-2566, 2006.
139. Qiu J, Nishimura M, Wang Y, Sims JR, Qiu S, Savitz SI, Salomone S, Moskowitz MA. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 28: 927-938, 2008.
140. Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 115: 165-175, 2014.
141. Read CM, Cary PD, Crane-Robinson C, Driscoll PC, Norman DG. Solution structure of a DNA-binding domain from HMG1. Nucleic Acids Res 21: 3427-3436, 1993.
142. Rehman J and Archer SL. A proposed mitochondrialmetabolic mechanism for initiation and maintenance of pulmonary arterial hypertension in fawn-hooded rats: the Warburg model of pulmonary arterial hypertension. Adv Exp Med Biol 661: 171-185, 2010.
143. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126, 1999.
144. Rossini A, Zacheo A, Mocini D, Totta P, Facchiano A, Castoldi R, Sordini P, Pompilio G, Abeni D, Capogrossi MC, Germani A. HMGB1-stimulated human primary cardiac fibroblasts exert a paracrine action on human and murine cardiac stem cells. J Mol Cell Cardiol 44: 683-693, 2008.
145. Rouhiainen A, Imai S, Rauvala H, Parkkinen J. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost 84: 1087-1094, 2000.
146. Roussel BD, Mysiorek C, Rouhiainen A, Jullienne A, Parcq J, Hommet Y, Culot M, Berezowski V, Cecchelli R, Rauvala H, Vivien D, Ali C. HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator. J Cell Sci 124: 2070-2076, 2011.
147. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Muller S, Iannacone M, Traversari C, Bianchi ME, Manfredi AA. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5: 825-830, 2004.
148. Rubartelli A and Sitia R. Stress as an intercellular signal: the emergence of stress-associated molecular patterns (SAMP). Antioxid Redox Signal 11: 2621-2629, 2009.
149. Sachdev U, Cui X, Hong G, Namkoong S, Karlsson JM, Baty CJ, Tzeng E. High mobility group box 1 promotes endothelial cell angiogenic behavior in vitro and improves muscle perfusion in vivo in response to ischemic injury. J Vasc Surg 55: 180-191, 2012.
150. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Vascular endothelial growth factor receptor blockade by SU5416 combined with pulsatile shear stress causes apoptosis and subsequent proliferation of apoptosis-resistant endothelial cells. Chest 128: 610S-611S, 2005.
151. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.
152. Schiller M, Heyder P, Ziegler S, Niessen A, Classen L, Lauffer A, Lorenz HM. During apoptosis HMGB1 is translocated into apoptotic cell-derived membranous vesicles. Autoimmunity 46: 342-346, 2013.
153. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, Apuzzo T, De Marchis F, Pedotti M, Bachi A, Thelen M, Varani L, Mellado M, Proudfoot A, Bianchi ME, Uguccioni M. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 209: 551-563, 2012.
154. Schlueter C, Weber H, Meyer B, Rogalla P, Roser K, Hauke S, Bullerdiek J. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 166: 1259-1263, 2005.
155. Semino C, Angelini G, Poggi A, Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 106: 609-616, 2005.
156. Shin JH, Lee HK, Lee HB, Jin Y, Lee JK. Ethyl pyruvate inhibits HMGB1 phosphorylation and secretion in activated microglia and in the postischemic brain. Neurosci Lett 558: 159-163, 2014.
157. Søensen M, Pedersen S, Møelvang R, Skov-Jensen J, Flyvbjerg A. Plasma high-mobility group box 1 levels predict mortality after ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 4: 281-286, 2011.
158. Sorensen MV, Pedersen S, Mogelvang R, Skov-Jensen J, Flyvbjerg A. Plasma high-mobility group box 1 levels predict mortality after ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 4: 281-286, 2011.
159. Sparatore B, Patrone M, Passalacqua M, Pedrazzi M, Gaggero D, Pontremoli S, Melloni E. Extracellular processing of amphoterin generates a peptide active on erythroleukaemia cell differentiation. Biochem J 357: 569-574, 2001.
160. Stark RJ, Aghakasiri N, Rumbaut RE. Platelet-derived Toll-like receptor 4 (Tlr-4) is sufficient to promote microvascular thrombosis in endotoxemia. PLoS One 7: e41254, 2012.
161. Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta 1799: 101-113, 2010.
162. Stros M, Launholt D, Grasser KD. The HMG-box: a versatile protein domain occurring in a wide variety ofDNAbinding proteins. Cell Mol Life Sci 64: 2590-2606, 2007.
163. Sun M, Dawood F, Wen WH, Chen M, Dixon I, Kirshenbaum LA, Liu PP. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 110: 3221-3228, 2004.
164. Takahashi M. High-mobility group box 1 protein (HMGB1) in ischaemic heart disease: beneficial or deleterious Cardiovasc Res 80: 5-6, 2008.
165. Tanaka R, Fujita M, Tsuruta R, Fujimoto K, Aki HS, Kumagai K, Aoki T, Kobayashi A, Izumi T, Kasaoka S, Yuasa M, Maekawa T. Urinary trypsin inhibitor suppresses excessive generation of superoxide anion radical, systemic inflammation, oxidative stress, endothelial injury in endotoxemic rats. Inflamm Res 59: 597-606, 2010.
166. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, Zeh HJ, Lotze MT. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 29: 5299-5310, 2010.
167. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ, 3rd, Lotze MT. Endogenous HMGB1 regulates autophagy. J Cell Biol 190: 881-892, 2010.
168. Tang D, Kang R, Livesey KM, Zeh HJ, 3rd, Lotze MT. High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal 15: 2185-2195, 2011.
169. Tang D, Kang R, Zeh HJ, 3rd, Lotze MT. High-mobility group box 1, oxidative stress, disease. Antioxid Redox Signal 14: 1315-1335, 2011.
170. Tang SC, Wang YC, Li YI, Lin HC, Manzanero S, Hsieh YH, Phipps S, Hu CJ, Chiou HY, Huang YS, Yang WS, Mattson MP, Arumugam TV, Jeng JS. Functional role of soluble receptor for advanced glycation end products in stroke. Arterioscler Thromb Vasc Biol 33: 585-594, 2013.
171. Thomas JO. HMG1 and 2: architectural DNA-binding proteins. Biochem Soc Trans 29: 395-401, 2001.
172. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8: 487-496, 2007.
173. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, Andersson U, Yang H, Tracey KJ, Andersson J, Palmblad JE. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 254: 375-385, 2003.
174. Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao Z, Peng X, Stolz DB, Geller DA, Rosengart MR, Billiar TR. HMGB1 release induced by liver ischemia involves Tolllike receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 204: 2913-2923, 2007.
175. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, Yang H, Li J, Tracey KJ, Geller DA, Billiar TR. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201: 1135-1143, 2005.
176. Tsung A, Tohme S, Billiar TR. High mobility group box-1 in sterile inflammation. J Intern Med 276: 425-443, 2014.
177. Tzeng HP, Fan J, Vallejo JG, Dong JW, Chen X, Houser SR, Mann DL. Negative inotropic effects of highmobility group box 1 protein in isolated contracting cardiac myocytes. Am J Physiol Heart Circ Physiol 294: H1490-H1496, 2008.
178. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F, Liu J, Antonelli A, Preti A, Raeli L, Shams SS, Yang H, Varani L, Andersson U, Tracey KJ, Bachi A, Uguccioni M, Bianchi ME. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 209: 1519-1528, 2012.
179. Vogelgesang A, May VE, Grunwald U, Bakkeboe M, Langner S, Wallaschofski H, Kessler C, Broker BM, Dressel A. Functional status of peripheral blood T-cells in ischemic stroke patients. PLoS One 5: e8718, 2010.
180. Volz HC, Kaya Z, Katus HA, Andrassy M. The role of HMGB1/RAGE in inflammatory cardiomyopathy. Semin Thromb Hemost 36: 185-194, 2010.
181. Volz HC, Seidel C, Laohachewin D, Kaya Z, Muller OJ, Pleger ST, Lasitschka F, Bianchi ME, Remppis A, Bierhaus A, Katus HA, Andrassy M. HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res Cardiol 105: 805-820, 2010.
182. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999.
183. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, Tracey KJ. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126: 389-392, 1999.
184. Wang L, Zhang X, Liu L, Cui L, Yang R, Li M, Du W. Tanshinone II A down-regulates HMGB1, RAGE, TLR4, NF-kappaB expression, ameliorates BBB permeability and endothelial cell function, protects rat brains against focal ischemia. Brain Res 1321: 143-151, 2010.
185. Wang L, Zhang X, Liu L, Yang R, Cui L, Li M. Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kappaB expression. Neurosci Lett 471: 152-156, 2010.
186. Wang N, Guo QL, Ye Z, Xia PP, Wang E, Yuan YJ. Preconditioning of intravenous parecoxib attenuates focal cerebral ischemia/reperfusion injury in rats. Chin Med J (Engl) 124: 2004-2008, 2011.
187. Wang N, Min X, Li D, He P, Zhao L. Geranylgeranylacetone protects against myocardial ischemia and reperfusion injury by inhibiting high-mobility group box 1 protein in rats. Mol Med Rep 5: 521-524, 2012.
188. Wang XY, Dong WP, Bi SH, Pan ZG, Yu H, Wang XW, Ma T, Wang J, Zhang WD. Protective effects of osthole against myocardial ischemia/reperfusion injury in rats. Int J Mol Med 32: 365-372, 2013.
189. Wartha F and Henriques-Normark B. ETosis: a novel cell death pathway. Sci Signal 1: pe25, 2008.
190. Willingham SB, Allen IC, Bergstralh DT, Brickey WJ, Huang MT, Taxman DJ, Duncan JA, Ting JP. NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, HMGB1 release via inflammasome-dependent and-independent pathways. J Immunol 183: 2008-2015, 2009.
191. Wolfson RK, Chiang ET, Garcia JG. HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvasc Res 81: 189-197, 2011.
192. Wyss CA, Neidhart M, Altwegg L, Spanaus KS, Yonekawa K, Wischnewsky MB, Corti R, Kucher N, Roffi M, Eberli FR, Amann-Vesti B, Gay S, von Eckardstein A, Luscher TF, Maier W. Cellular actors, Toll-like receptors, local cytokine profile in acute coronary syndromes. Eur Heart J 31: 1457-1469, 2010.
193. Xiong XX, Gu LJ, Shen J, Kang XH, Zheng YY, Yue SB, Zhu SM. Probenecid protects against transient focal cerebral ischemic injury by inhibiting HMGB1 release and attenuating AQP4 expression in mice. Neurochem Res 39: 216-224, 2014.
194. Xu H, Yao Y, Su Z, Yang Y, Kao R, Martin CM, Rui T. Endogenous HMGB1 contributes to ischemiareperfusion-induced myocardial apoptosis by potentiating the effect of TNF-a/JNK. Am J Physiol Heart Circ Physiol 300: H913-H921, 2011.
195. Yamada S, Yakabe K, Ishii J, Imaizumi H, Maruyama I. New high mobility group box 1 assay system. Clin Chim Acta 372: 173-178, 2006.
196. Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, Zhang RY, Chen QJ, Shen WF. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205: 544-548, 2009.
197. Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, chemotaxis. J Leukoc Biol 93: 865-873, 2013.
198. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, Lu B, Chavan S, Rosas-Ballina M, Al-Abed Y, Akira S, Bierhaus A, Erlandsson-Harris H, Andersson U, Tracey KJ. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 107: 11942-11947, 2010.
199. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101: 296-301, 2004.
200. Yang P-S, Kim D-H, Kang W-J, Chang H-J. Inhibition of pro-inflammatory cytokine HMGB1 attenuate disease progression of pulmonary arterial hypertension in rats. Circulation 122: A16928, 2010.
201. Yang QW, Lu FL, Zhou Y, Wang L, Zhong Q, Lin S, Xiang J, Li JC, Fang CQ, Wang JZ. HMBG1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. J Cereb Blood Flow Metab 31: 593-605, 2011.
202. Yao HC, Zhao AP, Han QF, Wu L, Yao DK, Wang LX. Correlation between serum high-mobility group box-1 levels and high-sensitivity C-reactive protein and troponin I in patients with coronary artery disease. Exp Ther Med 6: 121-124, 2013.
203. Youn JH and Shin JS. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol 177: 7889-7897, 2006.
204. Zhang H, Gong Y, Wang Z, Jiang L, Chen R, Fan X, Zhu H, Han L, Li X, Xiao J, Kong X. Apelin inhibits the proliferation and migration of rat PASMCs via the activation of PI3K/Akt/mTOR signal and the inhibition of autophagy under hypoxia. J Cell Mol Med 18: 542-553, 2014.
205. Zhang J, Takahashi HK, Liu K, Wake H, Liu R, Maruo T, Date I, Yoshino T, Ohtsuka A, Mori S, Nishibori M. Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke 42: 1420-1428, 2011.
206. Zhou P, Li YQ, Li WD, Han TS, Yang SJ, Yao YM, Zhang YY, Yu Y. [Changes in serum high mobility group box-1 protein and high-sensitivity C-reactive protein in patients with acute cerebral infarction and their clinical significance]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 24: 265-268, 2012.
207. Zhou Y, Xiong KL, Lin S, Zhong Q, Lu FL, Liang H, Li JC, Wang JZ, Yang QW. Elevation of high-mobility group protein box-1 in serum correlates with severity of acute intracerebral hemorrhage. Mediators Inflamm 2010, 2010.
208. Zhu XD, Chen JS, Zhou F, Liu QC, Chen G, Zhang JM. Relationship between plasma high mobility group box-1 protein levels and clinical outcomes of aneurysmal subarachnoid hemorrhage. J Neuroinflammation 9: 194, 2012.
209. Zimmer S, Grebe A, Latz E. Danger signaling in atherosclerosis. Circ Res 116: 323-340, 2015.